CJ Bioscience, Inc. (KOSDAQ:311690)
South Korea
· Delayed Price · Currency is KRW 7,920.00
-110.00 (-1.37%)
At close: Apr 29, 2026
CJ Bioscience Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 10,339 | 8,309 | 64,095 | 49,324 | 62,060 | Upgrade
|
| Short-Term Investments | 40,500 | 67,000 | - | - | 18,020 | Upgrade
|
| Cash & Short-Term Investments | 50,839 | 75,309 | 64,095 | 49,324 | 80,080 | Upgrade
|
| Cash Growth | -32.49% | 17.50% | 29.95% | -38.41% | 103.89% | Upgrade
|
| Accounts Receivable | 418.8 | 72.57 | 160.91 | 303.82 | 233.62 | Upgrade
|
| Other Receivables | 432.46 | 623.2 | 178.66 | 523.06 | 474.16 | Upgrade
|
| Receivables | 851.26 | 695.77 | 339.57 | 826.88 | 707.78 | Upgrade
|
| Inventory | 185.13 | 128.75 | 157.82 | 76.16 | 145.83 | Upgrade
|
| Prepaid Expenses | 218.73 | 294.56 | 355.71 | 446.57 | 259.18 | Upgrade
|
| Other Current Assets | 384.56 | 333.6 | 262.22 | 258.72 | 362.03 | Upgrade
|
| Total Current Assets | 52,478 | 76,762 | 65,210 | 50,932 | 81,555 | Upgrade
|
| Property, Plant & Equipment | 6,637 | 8,907 | 12,707 | 14,364 | 9,856 | Upgrade
|
| Long-Term Investments | 2 | 2 | 2 | 2 | 0 | Upgrade
|
| Other Intangible Assets | 11,778 | 12,499 | 12,397 | 1,016 | 114.13 | Upgrade
|
| Other Long-Term Assets | 1,442 | 1,439 | 811.16 | 25,075 | 24,830 | Upgrade
|
| Total Assets | 72,337 | 99,610 | 91,128 | 91,389 | 116,355 | Upgrade
|
| Accounts Payable | 378.32 | 220.83 | 122.82 | 336.65 | 287.75 | Upgrade
|
| Accrued Expenses | 2,229 | 3,234 | 3,966 | 3,996 | 140.94 | Upgrade
|
| Short-Term Debt | 6,984 | 6,365 | 3,971 | 23,588 | 18,441 | Upgrade
|
| Current Portion of Leases | 1,932 | 1,824 | 1,869 | 1,547 | 1,361 | Upgrade
|
| Other Current Liabilities | 3,035 | 6,882 | 4,793 | 5,511 | 3,606 | Upgrade
|
| Total Current Liabilities | 14,558 | 18,525 | 14,722 | 34,979 | 23,836 | Upgrade
|
| Long-Term Leases | 1,495 | 1,162 | 2,692 | 3,831 | 4,088 | Upgrade
|
| Pension & Post-Retirement Benefits | - | - | 65.47 | - | - | Upgrade
|
| Other Long-Term Liabilities | 2,645 | 2,166 | 2,152 | 2,924 | 577.4 | Upgrade
|
| Total Liabilities | 18,698 | 21,853 | 19,633 | 41,734 | 28,502 | Upgrade
|
| Common Stock | 6,533 | 6,533 | 4,556 | 2,939 | 2,937 | Upgrade
|
| Additional Paid-In Capital | 189,419 | 189,419 | 151,426 | 108,066 | 112,186 | Upgrade
|
| Retained Earnings | -143,313 | -119,067 | -85,951 | -62,738 | -28,035 | Upgrade
|
| Comprehensive Income & Other | 1,001 | 872.04 | 1,465 | 1,389 | 765.25 | Upgrade
|
| Shareholders' Equity | 53,639 | 77,757 | 71,496 | 49,655 | 87,853 | Upgrade
|
| Total Liabilities & Equity | 72,337 | 99,610 | 91,128 | 91,389 | 116,355 | Upgrade
|
| Total Debt | 10,411 | 9,351 | 8,533 | 28,966 | 23,891 | Upgrade
|
| Net Cash (Debt) | 40,427 | 65,958 | 55,562 | 20,357 | 56,190 | Upgrade
|
| Net Cash Growth | -38.71% | 18.71% | 172.93% | -63.77% | 1501.15% | Upgrade
|
| Net Cash Per Share | 3093.73 | 7112.48 | 7843.75 | 3463.50 | 13214.21 | Upgrade
|
| Filing Date Shares Outstanding | 13.07 | 13.07 | 9.11 | 5.88 | 5.87 | Upgrade
|
| Total Common Shares Outstanding | 13.07 | 13.07 | 9.11 | 5.88 | 5.87 | Upgrade
|
| Working Capital | 37,920 | 58,236 | 50,488 | 15,953 | 57,718 | Upgrade
|
| Book Value Per Share | 4102.87 | 5951.30 | 7845.89 | 8446.71 | 14957.10 | Upgrade
|
| Tangible Book Value | 41,861 | 65,257 | 59,098 | 48,640 | 87,739 | Upgrade
|
| Tangible Book Value Per Share | 3201.95 | 4994.63 | 6485.40 | 8273.89 | 14937.67 | Upgrade
|
| Machinery | 13,053 | 14,051 | 13,686 | 10,339 | 4,411 | Upgrade
|
| Construction In Progress | - | - | - | 521.7 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.